Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David A Isenberg

Showing results (191-200 of 280) with videos related to

Pageof 28
Sort By:
Rheumatology (Oxford, England)|February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosusDaniel J Wallace, David A Isenberg, Eric F Morand, et al.
Journal of Autoimmunity|July 24, 2018
Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndromeVera M Ripoll, Francesca Pregnolato, Simona Mazza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathwaysAnastasia Lambrianides, Christopher J Carroll, Silvia S Pierangeli, et al.
Rheumatology (Oxford, England)|November 12, 2022
Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupusChris Wincup, Nicky Dunn, Caroline Ruetsch-Chelli, et al.
The Lancet. Rheumatology|February 9, 2023
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trialMuhammad Shipa, Liliana R Santos, Dao X Nguyen, et al.
Human Molecular Genetics|December 3, 2003
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosusAndrew I Russell, Deborah S Cunninghame Graham, Christopher Shepherd, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Interrater reliability and aspects of validity of the myositis damage indexShabina M Sultan, Elizabeth Allen, Robert G Cooper, et al.
Blood|October 11, 2014
Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndromeVera M Ripoll, Anastasia Lambrianides, Silvia S Pierangeli, et al.
Rheumatology (Oxford, England)|November 17, 2021
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Venkat R Reddy, Ruth J Pepper, Kavina Shah, et al.
Arthritis Research & Therapy|March 2, 2006
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtypeHector Chinoy, Fiona Salway, Noreen Fertig, et al.
Pageof 28

Showing results (191-200 of 280) with videos related to

Sort By:
Pageof 28
Rheumatology (Oxford, England)|February 6, 2021
Safety and clinical activity of atacicept in the long-term extension of the phase 2b ADDRESS II study in systemic lupus erythematosusDaniel J Wallace, David A Isenberg, Eric F Morand, et al.
Journal of Autoimmunity|July 24, 2018
Gene expression profiling identifies distinct molecular signatures in thrombotic and obstetric antiphospholipid syndromeVera M Ripoll, Francesca Pregnolato, Simona Mazza, et al.
Journal of Immunology (Baltimore, Md. : 1950)|May 21, 2010
Effects of polyclonal IgG derived from patients with different clinical types of the antiphospholipid syndrome on monocyte signaling pathwaysAnastasia Lambrianides, Christopher J Carroll, Silvia S Pierangeli, et al.
Rheumatology (Oxford, England)|November 12, 2022
Anti-rituximab antibodies demonstrate neutralizing capacity, associate with lower circulating drug levels and earlier relapse in lupusChris Wincup, Nicky Dunn, Caroline Ruetsch-Chelli, et al.
The Lancet. Rheumatology|February 9, 2023
Identification of biomarkers to stratify response to B-cell-targeted therapies in systemic lupus erythematosus: an exploratory analysis of a randomised controlled trialMuhammad Shipa, Liliana R Santos, Dao X Nguyen, et al.
Human Molecular Genetics|December 3, 2003
Polymorphism at the C-reactive protein locus influences gene expression and predisposes to systemic lupus erythematosusAndrew I Russell, Deborah S Cunninghame Graham, Christopher Shepherd, et al.
Annals of the Rheumatic Diseases|May 31, 2011
Interrater reliability and aspects of validity of the myositis damage indexShabina M Sultan, Elizabeth Allen, Robert G Cooper, et al.
Blood|October 11, 2014
Changes in regulation of human monocyte proteins in response to IgG from patients with antiphospholipid syndromeVera M Ripoll, Anastasia Lambrianides, Silvia S Pierangeli, et al.
Rheumatology (Oxford, England)|November 17, 2021
Disparity in peripheral and renal B-cell depletion with rituximab in systemic lupus erythematosus: an opportunity for obinutuzumab?Venkat R Reddy, Ruth J Pepper, Kavina Shah, et al.
Arthritis Research & Therapy|March 2, 2006
In adult onset myositis, the presence of interstitial lung disease and myositis specific/associated antibodies are governed by HLA class II haplotype, rather than by myositis subtypeHector Chinoy, Fiona Salway, Noreen Fertig, et al.
Pageof 28